Ginsenosides, potential TMPRSS2 inhibitors, a trade-off between the therapeutic combination for anti-PD-1 immunotherapy and the treatment of COVID-19 infection of LUAD patients.

Meng, Mei; Gao, Rui; Liu, Zixue; Liu, Fengxiang; Du, Shiyu; Song, Yizhi; He, Jian

Meng, Mei; Gao, Rui; Liu, Zixue; Liu, Fengxiang; Du, Shiyu; Song, Yizhi; He, Jian.

Afiliación

Meng M; State Key Laboratory of Oncogenes and Related Genes, Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Gao R; State Key Laboratory of Oncogenes and Related Genes, Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Liu Z; State Key Laboratory of Oncogenes and Related Genes, Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Liu F; CAS Key Laboratory of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou, China.
Du S; Engineering Laboratory of Nuclear Energy Materials, Ningbo Institute of Materials Technology and Engineering, Chinese Academy of Sciences, Ningbo, China.
Song Y; School of Materials Science and Engineering, China University of Petroleum (East China), Qingdao, China.
He J; School of Computer Science, China University of Petroleum (East China), Qingdao, China.

Front Pharmacol ; 14: 1085509, 2023.

Article en En | MEDLINE | ID: mdl-36992839

Palabras clave

LUAD; TMPRSS2; biomarker; ginsenosides; prognosis; tumor-infiltrating lymphocytes

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 4_TD Problema de salud: 4_covid_19 Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google